A pharmacovigilance study to determine onset of Adverse events following immunization with COVID-19 mRNA vaccines (Spikevax and Comirnaty) in pediatric population
Latest Information Update: 18 Aug 2022
Price :
$35 *
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 18 Aug 2022 New trial record
- 28 Jun 2022 Results of an analysis assessing safety of mRNA-platform based COVID-19 vaccines from European pharmacovigilance database Eudravigilance presented at the 15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 2022